Answers are grounded in this paper and cite their sources.
Structure-based drug design was used to incorporate the traditional hydroxyethyl amine aspartyl protease inhibitor motif into 2,3,5-substituted imidazolidin-4-one structures with good BACE-1 enzyme inhibitory potency. These compounds represent a promising drug target for Alzheimer′s disease-modifying therapy and are therefore of interest to the medicinal chemistry community.
No takes yet. Share an insight, caveat, or question.
Barrow et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: